Torbay Pharmaceuticals opens new £26 million pharmaceutical manufacturing unit
The new facilities enable to company to further grow and flourish.
Torbay Pharmaceuticals, part of Torbay and South Devon NHS Foundation Trust, has officially opened its new manufacturing unit in Paignton.
The Trust’s Chairman (Sir Richard Ibbotson), Managing Director (Emma Rooth), Technical Director (Mark Andrews), together with staff and other partners, marked the milestone with a celebratory opening ceremony with Sir Richard unveiling a commemorative plaque.
Sir Richard Ibbotson, Chairman of Torbay and South Devon NHS Foundation Trust, said: “We are incredibly proud of Torbay Pharmaceuticals and all that they have achieved over the years. Not only have they created a range of highly skilled career opportunities, but they generate income which directly supports the health and care of local people. This is a first-rate example of what innovation in the NHS can contribute to local communities.
“These fabulous new facilities offer a modern, class-leading environment which will enable Torbay Pharmaceuticals to further grow and flourish. I, on behalf of the Trust Board, cannot thank everyone enough for their hard work in seeing this superb project come to fruition.”
Emma Rooth, Managing Director of Torbay Pharmaceuticals, said: “Torbay Pharmaceuticals is proud to be such a successful part of Torbay and South Devon NHS Foundation Trust. Being part of the NHS enables us to have our finger on the pulse of healthcare needs and respond appropriately with new products, plugging shortages and anticipating the latest developments in medical science.
“Since the establishment of the original pharmaceutical department at Torbay Hospital back in the 1970s, we have grown from strength to strength to meet not only our local population’s needs, but also the needs of the wider NHS and healthcare providers globally.
“The official opening of our new class-leading sterile product facility is a very exciting time for Torbay Pharmaceuticals. By strengthening our production capabilities and ensuring the delivery of high-quality products for our patients through this investment, we have created the platform upon which we can achieve significant growth for the organisation, its people and the region.”
Bryan Taylor, UK Property Director for Balfour Beatty, said: “The official opening of Torbay Pharmaceuticals new manufacturing unit in Paignton marks the completion of 8 years of involvement by Balfour Beatty. Having secured the plot, designed, developed and constructed the facility, the project reflects the all-encompassing skills, expertise and capabilities of Balfour Beatty in providing clients with whole project life cycle solutions.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.